Q4 2024 Quanterix Corp Earnings Call Transcript
Key Points
- Quanterix Corp (QTRX) delivered its seventh consecutive quarter of double-digit revenue growth, with a reported revenue of $35.2 million, marking an 11% increase year-over-year.
- The company's Accelerator lab revenue grew by 22%, driven by strong demand for testing services in clinical trials and custom asset development.
- Non-GAAP gross margin improved by 300 basis points to 57.7%, attributed to higher pricing and improved operating efficiency.
- Quanterix Corp (QTRX) has successfully reduced its cash usage by 31% to $4.4 million in the fourth quarter.
- The company is expanding its addressable market significantly through the proposed acquisition of Akoya Biosciences, which is expected to enhance scale and profitability, with projected synergies of $40 million by 2026.
- Instrument revenue declined by 7% year-over-year, although it showed a 29% sequential increase.
- The company is facing challenges in the academic market due to market volatility and NIH funding pressures, which could impact revenue growth.
- Quanterix Corp (QTRX) is experiencing a slower start to 2025 in its Accelerator lab due to a lower number of large pharma projects in the first half of the year.
- The company's guidance for 2025 indicates a modest revenue growth of 2% to 6%, which is below market expectations.
- There is market skepticism regarding the valuation of the Akoya acquisition, with concerns about Akoya's debt and cash burn.
Thank you for standing by. My name is Kathleen and I will be your conference operator today.
At this time, I would like to welcome everyone to the Quanterix Corporation fourth-quarter 2024 earnings call.
(Operator Instructions) Thank you.
Now, I would like to turn the call over to Joshua Young, Head of Investor Relations. Please go ahead.
Thank you and good afternoon. With me on today's call are Masoud Toloue, Quanterix's President and CEO; and Vandana Sriram, Quanterix's Chief Financial Officer.
Today's call is being recorded and a replay of the call will be available on the Investors section of our website.
During the course of today's presentation, we will make forward-looking statements within the meaning of the US Private Securities Litigation Reform Act. These forward-looking statements are based on management's beliefs and assumptions as of today, March 17, 2025. We may not actually achieve the plans, intentions, or expectations disclosed in our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
